Evidence map›Paper›PMID 24525473›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2014

Morbidity and health care resource utilization in HIV-infected children after antiretroviral therapy initiation in Côte d'Ivoire, 2004-2009.

Sophie Desmonde, Jean-Bosco Essanin, Addi E Aka, Eugène Messou, Madeleine Amorissani-Folquet, Virginie Rondeau, Andrea Ciaranello, Valériane Leroy

Abstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Article
  3. Observational
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Sophie Desmonde*Center INSERM U897, Epidémiologie Biostatistiques, Bordeaux, France; †Université Bordeaux, ISPED, Center INSERM U897, Epidémiologie Biostatistiques, Bordeaux, France; ‡Université de Cocody, Abidjan, Côte d'Ivoire; §CePReF, ACONDA, Abidjan Côte d'Ivoire; ‖Department of Pediatrics, Cocody University Hospital, Abidjan, Côte d'Ivoire; and ¶Massachusetts General Hospital, Boston, MA.
Jean-Bosco Essanin
Addi E Aka
Eugène Messou
Madeleine Amorissani-Folquet
Virginie Rondeau
Andrea Ciaranello
Valériane Leroy
Inserm · FRCentre Hospitalier Universitaire de Cocody · CISociété de Développement des Forêts · CIMassachusetts General Hospital · US

Funding

LOC-IMPAACT Leadership GroupPharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the USUM1AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI Jennifer Jao, Sharon A Nachman · 2011 to 2026
$278.1M
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) GroupU01AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI JACKSON, J BROOKS · 2006 to 2010
$109.7M
WADA (West Africa Database on Antiretroviral Therapy) CollaborationU01AI069919 · NIAID · UNIVERSITY OF BORDEAUX II · PI Didier Koumavi Ekouevi, Antoine Jaquet · 2006 to 2026
$29.9M
Optimizing HIV Care in Less Developed CountriesR01AI058736 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Kenneth Alan Freedberg, Emily Parker Hyle · 2004 to 2026
$21.5M
Optimizing Outcomes for HIV-Exposed and HIV-Infected Children in South AfricaK01AI078754 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CIARANELLO, ANDREA LYNNE · 2009 to 2013
$685k
NIAID NIH HHS AI068632 SNIAID NIH HHS K01 AI078754NIAID NIH HHS K01AI078754NIAID NIH HHS R01AI05873NIAID NIH HHS R01 AI058736NIAID NIH HHS U01 AI068632NIAID NIH HHS U01 AI069919NIAID NIH HHS U01AI069919NIAID NIH HHS UM1 AI068632PHS HHS R01A1058736
6 · The paper itself

Abstract

backgroundWe describe severe morbidity and health care resource utilization (HCRU) among HIV-infected children on antiretroviral therapy (ART) in Abidjan, Côte d'Ivoire.

methodsAll HIV-infected children enrolled in an HIV-care program (2004-2009) were eligible for ART initiation until database closeout, death, ART interruption, or loss to follow-up. We calculated incidence rates (IRs) of density per 100 child-years (CYs) for severe morbidity, HCRU (outpatient care and inpatient care), and associated factors using frailty models with a Weibull distribution.

resultsOf 332 children with a median age of 5.7 years and median follow-up of 2.5 years, 65.4% were severely immunodeficient by World Health Organization (WHO) criteria, and all received cotrimoxazole prophylaxis. We recorded 464 clinical events in 228 children; the overall IR was 57.6/100 CYs [95% confidence interval (CI): 52.1 to 62.5]. Severe morbidity was more frequent in children on protease inhibitor (PI)-based ART compared to those on other regimens [adjusted hazards ratio (aHR): 1.83; 95% CI: 1.35 to 2.47] and to those moderately/severely immunodeficient compared to those not (aHR: 1.57; 95% CI: 1.13 to 2.18 and aHR: 2.53; 95% CI: 1.81 to 3.55, respectively). Of the 464 events, 371 (80%) led to outpatient care (IR: 45.6/100 CYs) and 164 (35%) to inpatient care (IR: 20.2/100 CYs). In adjusted analyses, outpatient care was significantly less frequent in children older than 10 years compared with children younger than 2 years (aHR: 0.49; 95% CI: 0.31 to 0.78) and in those living furthest from clinics compared with those living closest (aHR: 0.65; 95% CI: 0.47 to 0.90). Both inpatient and outpatient HCRU were negatively associated with cotrimoxazole prophylaxis.

conclusionsDespite ART, HIV-infected children still require substantial utilization of health care services.

Indexed as

Antiretroviral Therapy, Highly ActiveHealth FacilitiesAdolescentAnti-Retroviral AgentsChildChild, PreschoolCote d'IvoireFemaleHIV InfectionsHumansInfantMaleRetrospective StudiesAnti-Retroviral Agents

Identifiers

PMID24525473
PMCPMC3982324
OpenAlexW2055664053

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.